
[¹²⁵I] AMINOPOTENTIDINE

Product Number: NEX431



LOT SPECIFIC INFORMATION

CALCULATED AS OF:	20-Jan-2025			
LOT NUMBER:	LN22150			
SPECIFIC ACTIVITY:	2200	TBq/mmol Ci/mmol MBq/μg μCi/μg		
CONCENTRATION:	5.8 157.9	MBq/ml µCi/ml		
RADIOCHEMICAL PURITY	>95%			

Package Size Information

Package Size				
as of	Volume			
21-Feb-2025				
370 kBq	0.10 mL			
10 µCi				
925 kBq	0.25 mL			
25 µCi				
92.5 MBq	2.5 mL			
250 µCi				

MOLECULAR WEIGHT: 601.6

PACKAGING: [¹²⁵I]-Aminopotentidine is supplied in an ethanol and water solution and dispensed in TPX vials. It is shipped ambient.

STABILITY AND STORAGE: [¹²⁵I]-Aminopotentidine should be stored at 2-8°C. Under these conditions the product has been shown to stable for at least four weeks after the fresh lot date.

SPECIFIC ACTIVITY: The initial specific activity is 2200 Ci/mmol, (81.4 TBq/mmol), 3657 µCi/µg (135 MBq/µg). Upon decay, the product undergoes decay catastrophe and the specific activity remains constant with time. However, it is not known what molecular fragments are generated from the decay event or what functional activity these fragments may have in different assays. References on ¹²⁵I decay and decay catastrophe of ¹²⁵I labeled compounds are available.¹⁻⁵

RADIOCHEMICAL PURITY: Initially greater than 95% radiochemically pure as determined by HPLC.

PREPARATIVE PROCEDURE: [¹²⁵I]-Aminopotentidine is radioiodinated with no carrier added ¹²⁵I using a modification of the Hunter and Greenwood method⁶ (chloramine-T) and purified by reversed phase HPLC.

AVAILABILITY: [¹²⁵I]-Aminopotentidine is routinely available from stock and is prepared fresh and packaged for shipment on the third Monday of each month. Please inquire for larger package sizes.

APPLICATIONS: [¹²⁵I]-Aminopotentidine has been shown to work in receptor binding and autoradiography and is an antagonist for histamine (H₂) receptors.⁷

HAZARD WARNING: This product contains a chemical(s) known to the state of California to cause cancer. This product also contains a component which is harmful by contact, ingestion and inhalation. It is irritating to the eyes, skin and respiratory tract and is to the X431-R-REV01

Revvity Proprietary Information

RADIATION UNSHIELDED: 280mR/hr/mCi at vial surface.

REFERENCES:

- 1. Doyle, V.M., Buhler, F.R., Burgisser, E., *Eur. J. Pharm.* <u>99</u> 353 (1984).
- 2. Schmidt, J., *J. Biol. Chem.* <u>259</u> 1160 (1984).
- 3. Loring, R.H., Jones, S.W., Matthews-Bellinger, J., Salpeter, M.M., J. Biol. Chem. 257 1418 (1982).
- 4. Berridge, M.S., Jiang, V.W., Welch, M.J., Rad. Res. 82 467 (1980).
- 5. Charlton, D.E., Rad. Res. 107 163 (1986).
- 6. Hunter, W.M. and Greenwood, F.C., Nature <u>194</u> 495 (1962).
- 7. Ruat, M., Traiffort, E., et al, Proc. Natl. Acad. Sci. USA, Vol 87, p.1658 March 1990

IODINE-125 DECAY CHART HALF LIFE=60 days

Radiations Gamma 35.5 keV (7%), X-ray K alpha 27 KeV (112%), K beta 31 keV (24%)

		(170), 701 (19)		. (=,,,,,					
DAYS	0	2	4	6	8	10	12	14	16
0	1	0.977	0.955	0.933	0.912	0.891	0.871	0.851	0.831
20	0.794	0.776	0.758	0.741	0.724	0.707	0.691	0.675	0.66
40	0.63	0.616	0.602	0.588	0.574	0.561	0.548	0.536	0.524
60	0.5	0.489	0.477	0.467	0.456	0.445	0.435	0.425	0.416
80	0.397	0.388	0.379	0.37	0.362	0.354	0.345	0.338	0.33
100	0.315	0.308	0.301	0.294	0.287	0.281	0.274	0.268	0.262
120	0.25	0.244	0.239	0.233	0.228	0.223	0.218	0.213	0.208

To obtain the correct radioactive concentration or amount for a date before the calibration date: divide by the decay factor corresponding to the number of days before the calibration date. To obtain the correct radioactive concentration or amount for a date after the calibration date: multiply by the decay factor corresponding to the number of days after the calibration date.

The information provided in this document is valid for the specified lot number and date of analysis. This information is for reference purposes only and does not constitute a warranty or guarantee of the product's suitability for any specific use. Revvity, Inc., its subsidiaries, and/or affiliates (collectively, "Revvity") do not assume any liability for any errors or damages arising from the use of this document or the product described herein. REVVITY EXPRESSLY DISCLAIMS ALL WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, REGARDLESS OF WHETHER ORAL OR WRITTEN, EXPRESS OR IMPLIED, ALLEGEDLY ARISING FROM ANY USAGE OF ANY TRADE OR ANY COURSE OF DEALING, IN CONNECTION WITH THE USE OF INFORMATION CONTAINED HEREIN OR THE PRODUCT ITSELF.

revvity

Revvity, Inc. 940 Winter Street Waltham, MA 02451 USA

(800) 762-4000 www.revvity.com For a complete listing of our global offices, visit <u>www.revvity.com</u> Copyright ©2023, Revvity, Inc. All rights reserved.